Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial resultsSabino De Placido, Grazia Arpino, Mariangela Ciccarese et al.|The Breast|2018Cited by 35
PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in ItalyFrancesco Cognetti, Sandro Barni, Riccardo Masetti et al.|npj Breast Cancer|2021Cited by 29
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational studyFrancesco Schettini, Lucia Del Mastro, Benedetta Conte et al.|ESMO Open|2021Cited by 22
Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patientsAdriano Gravina, Federica Perrone, P. Gargiulo et al.|ESMO Open|2025Cited by 8
105P CDK4/6 inhibitors in hormone receptor-positive, HER2-negative, locally advanced breast cancer (LABC): Biological and clinical activity, and post-surgical approachesSara Parola, C. De Angelis, Vincenzo Di Lauro et al.|Annals of Oncology|2022Cited by 1